Biogen’s Twisting Path To The Aducanumab Advisory Committee

Our graphical timeline shows Aducanumab’s ups and downs, from IND to accepted BLA, and the many meetings with US FDA staff that helped move the program forward.

Different paths (Lightspring/Shutterstock.com)
• Source: Shutterstock

Our graphical timeline shows Aducanumab’s ups and downs, from IND to accepted BLA, and the many meetings with US FDA staff that helped move the program forward.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers